Diflunisal
![]() | |
![]() | |
Clinical data | |
---|---|
Trade names | Dolobid |
AHFS/Drugs.com | Monograph |
MedlinePlus | a684037 |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 80-90% |
Protein binding | >99% |
Metabolism | Hepatic |
Elimination half-life | 8 to 12 hours |
Excretion | Renal |
Identifiers | |
| |
JSmol) | |
SMILES
| |
| |
(verify) |
Diflunisal is a
Mechanism of action
Like all NSAIDs, diflunisal acts by inhibiting the production of prostaglandins,[4] hormones which are involved in inflammation and pain. Diflunisal also has an antipyretic effect, but this is not a recommended use of the drug.[5]
It has been found to inhibit p300 and CREB-binding protein (CBP), which are epigenetic regulators that control the levels of proteins that cause inflammation or are involved in cell growth.[6]
It has been reported that diflunisal has some antibacterial activity in vitro against Francisella tularensis live vaccine strain (LVS).[7]
Duration of effect
Though diflunisal has an onset time of 1 hour, and maximum
Effectiveness of diflunisal is similar to other NSAIDs, but the duration of action is twelve hours or more. This means fewer doses per day are required for chronic administration. In acute use, it is popular in dentistry when a single dose after oral surgery can maintain analgesia until the patient is asleep that night.
Medical uses
- Pain, mild to moderate
- Osteoarthritis
- Rheumatoid arthritis
- Injury to tendons
- Inflammation
- ATTR amyloidosis
Amyloidosis
Both diflunisal
Side effects
In October 2020, the U.S. Food and Drug Administration (FDA) required the drug label to be updated for all nonsteroidal anti-inflammatory medications to describe the risk of kidney problems in unborn babies that result in low amniotic fluid.[15][16] They recommend avoiding NSAIDs in pregnant women at 20 weeks or later in pregnancy.[15][16]
Gastrointestinal
The inhibition of prostaglandins has the effect of decreasing the protection given to the stomach from its own acid. Like all NSAIDS, this leads to an increased risk of stomach ulcers, and their complications, with long-term use. Elderly users of diflunisal are at greater risk for serious GI events.
- Increased risk of GI events including bleeding, ulceration, and stomach or intestine perforation.
- Abdominal pain or cramps
- Constipation
- Gas
- Diarrhea
- Nausea and vomiting
- Dyspepsia
Cardiovascular
- Irregular heart beat
- Possible increased risk of serious and potentially fatal cardiovascular thrombotic events, MI, and stroke
- Risks may increase with duration of use and for cardiovascular disease history
Ear, nose, throat, and eye
- Ringing in the ears
- Yellowing of eyes
Central nervous system
- Drowsiness
- Dizziness
- Headache
- Insomnia
- Fatigue
- Somnolence
- Nervousness
Skin
- Swelling of the feet, ankles, lower legs, and hands
- Yellowing of skin
- Rash
- Ecchymosis
Contraindications
- urticaria
- 3rd trimester pregnancy
- Coronary artery bypass surgery (peri-op pain)
Cautions
]- Cardiovascular diseases
- Cardiac risk factors
- Hypertension
- Congestive heart failure
- Elderly or debilitated
- Impaired liver function
- Impaired kidney function
- Dehydration
- Fluid retention
- History of gastrointestinal bleeds/PUD
- Asthma
- Coagulopathy
- Smoker (tobacco use)
- Corticosteriod use
- Anticoagulant use
- Alcohol use
- Diuretic use
- ACE inhibitor use
Overdose
Deaths that have occurred from diflunisal usually involved mixed drugs and or extremely high dosage. The oral LD50 is 500 mg/kg. Symptoms of overdose include coma, tachycardia, stupor, and vomiting. The lowest dose without the presence of other medicines which caused death was 15 grams. Mixed with other medicines, a death at 7.5 grams has also occurred. Diflunisal usually comes in 250 or 500 mg, making it relatively hard to overdose by accident.
References
- FDA. Retrieved 22 Oct 2023.
- ISBN 3527306730.
- S2CID 11074565.
- S2CID 448875.
- ^ PMID 328032.
- ^ "New Metabolic Pathway Reveals Aspirin-Like Compound's Anti-Cancer Properties. June 2016". Archived from the original on 2016-06-04. Retrieved 2016-06-09.
- PMID 28652232.
- S2CID 24191409.
- PMID 8216032.
- S2CID 42504073.
- PMID 18326041.
- PMID 14711308.
- S2CID 40303434.
- PMID 24368466.
- ^ a b "FDA Warns that Using a Type of Pain and Fever Medication in Second Half of Pregnancy Could Lead to Complications". U.S. Food and Drug Administration (FDA) (Press release). 15 October 2020. Retrieved 15 October 2020.
This article incorporates text from this source, which is in the public domain.
- ^ a b "NSAIDs may cause rare kidney problems in unborn babies". U.S. Food and Drug Administration. 21 July 2017. Retrieved 15 October 2020.
This article incorporates text from this source, which is in the public domain.
External links
- Diflunisal: MedlinePlus Drug Information
- Dolobid Prescribing Information (manufacturer's website)
- Dolobid Medication Guide (manufacturer's website)
- "Single dose oral diflunisal for acute postoperative pain in adults" Archived 2010-05-21 at the Wayback Machine